Chimeric Fabs for Quantitative HBeAg Detection and HBV Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current assays for detecting Hepatitis B Virus (HBV) e-antigen (HBeAg) are non-quantitative and lack structural definition, leading to challenges in accurately diagnosing and treating chronic HBV infections, as they often cross-react with related antigens and do not effectively inhibit viral persistence or replication.

Innovation Solution

Development of a panel of chimeric Fabs against recombinant HBeAg, characterized for their binding affinity and specificity, which are used to create a sensitive and quantitative assay for HBeAg detection, including monoclonal antibodies that can inhibit cell growth or induce cell death, and are produced through recombinant expression in CHO or bacterial cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current assays for detecting HBeAg are used, then detection can be performed, but the assays are non-quantitative and lack structural definition leading to inaccurate diagnosis

Engineering Contradiction:

Improvedetection accuracyVSAvoiddiagnostic reliability

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent changes the detection parameters by using monoclonal antibodies with defined epitope specificities and standardized binding conditions, enabling quantitative measurement of HBeAg concentration while improving diagnostic reliability through consistent, reproducible results

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces non-specific detection mechanisms with specific antibody-antigen binding interactions, using the molecular recognition between monoclonal antibodies and HBeAg epitopes to achieve precise, quantitative detection that eliminates cross-reactivity issues

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Measurement precision

If existing HBeAg detection methods are used, then testing is possible, but they cross-react with related antigens reducing specificity

Engineering Contradiction:

Improvedetection specificityVSAvoidcross-reactivity

Core Design Contradiction:

Measurement precisionVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing monoclonal antibodies that recognize specific, localized epitopes on the HBeAg molecule. Each antibody is engineered to bind to a distinct epitope region, ensuring specificity and preventing cross-reactivity with related antigens like HBcAg

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the HBeAg detection into multiple specific epitope recognition events by using a panel of monoclonal antibodies, each targeting a different epitope. This segmentation allows the system to distinguish HBeAg from related antigens based on which epitopes are recognized

Inventive Principle:

Principle #1Segmentation

3Reliability

If conventional HBeAg assays are used, then detection can be performed, but they do not effectively inhibit viral persistence or replication

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidviral persistence

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses monoclonal antibodies as intermediary molecules that mediate the inhibition of viral persistence. The antibodies bind to HBeAg and prevent its function in promoting immune tolerance and viral persistence, thereby enabling effective therapeutic treatment

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the harmful role of HBeAg in promoting viral persistence into a beneficial target for therapy. By designing antibodies that specifically bind to HBeAg epitopes, the system transforms the antigen into a therapeutic target that, when blocked, eliminates viral persistence and enables effective treatment

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antibodies provide specific and quantitative detection of HBeAg, enabling effective therapeutic treatment and diagnostic detection of HBV infections, potentially reducing chronic infection and replication by inhibiting HBeAg-expressing cells.

Implementation Method 1

The invention provides a panel of chimeric Fabs against recombinant HBeAg... characterized for their binding affinity and specificity

Methodology Applied

Scientific EffectAntigen-antibody binding:

Implementation Method 2

monoclonal antibodies that can inhibit cell growth or induce cell death

Methodology Applied

Scientific EffectImmune-mediated cell death:

Data Source

PatentUS11827669B2Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection

Publication Date: 2023.11.28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

AI summary

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Hepatitis B Virus infection in mammals, and to methods of using those compositions of matter for the same.